



Research in Bat-Borne Zoonotic Viruses

Guest Editors:

Dr. Davide Lelli

Istituto Zooprofilattico
Sperimentale della Lombardia e
dell'Emilia Romagna "Bruno
Ubertini", IZSLER, Via Bianchi, 9 -
25124 Brescia, Italy.

Dr. Ana Moreno

Virology Department, Istituto
Zooprofilattico Sperimentale
della Lombardia ed Emilia-
Romagna, Via Bianchi 9, 25124
Brescia, Italy

Deadline for manuscript
submissions:

closed (30 September 2021)

Message from the Guest Editors

Dear Colleagues,

Bats are suggested to be important reservoir hosts of many zoonotic viruses that can cross species barriers to infect humans and other domestic or wild mammals, including lyssaviruses, henipaviruses, ebolaviruses, marburgviruses, and Mers and Sars-coronaviruses. A bat origin of the recent SARS-CoV-2 (2019-nCoV), responsible for COVID-19, which started in Wuhan (China) in December 2019, has also been hypothesized. It has been assumed that bats may have a “special” relationship with viruses based on physiological, ecological, evolutionary, and/or immunological aspects, which allow them to act as special reservoir hosts for a variety of viruses that lead to efficient pathogen maintenance, evolution, and spread.

In this Special Issue, we invite you to submit research papers and reviews on a wide range of research topics related to Bat-Borne Zoonotic Viruses. Topics of interest include (but are not limited to) epidemiology, diagnosis, pathogenesis, vaccines, immunology, virome of bats, genetic and antigenic characterization, viral evolution, and phylogenetic studies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)